Apricus Biosciences Closes $3.7 Million Registered Direct

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Apricus Biosciences Closes $3.7 Million Registered Direct Offering

SAN DIEGO, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI ), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has closed a registered direct offering of shares of common stock with institutional investors for gross proceeds of approximately $3.7 million.  Based on feedback from the Nasdaq stock market, Apricus and the investors mutually agreed to revise the size of the offering such that fewer shares of common stock were issued than previously announced. The purchase price per share remained the same.

The Company issued approximately 10.8 million registered shares of common stock at a purchase price of $0.345 per share.  Concurrently in a private placement, for each share of common stock purchased by an investor, such investor received from the Company an unregistered warrant to purchase 0.75 shares of common stock.  The warrants have an exercise price of $0.45 per share, will be exercisable six (6) months following the closing date and will expire 5 years from the initial exercise date.

Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC, acted as the exclusive placement agent in connection with this offering.

The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

The sale of shares of common stock and warrants was made pursuant to a securities purchase agreement, dated September 27, 2016, by and among the Company and the investors.  The Company and the investors terminated the previously announced securities purchase agreement, dated September 22, 2016, prior to the closing in order to complete an at the market offering for purposes of the Nasdaq listing rules. 

The shares of common stock described above (but not the warrants or the shares of common stock underlying the warrants) are being offered pursuant to a shelf registration statement (File No. 333-198066).  Such shares of common stock may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

The warrants and the shares of common stock underlying the warrants issued in the offering have not been registered under the Securities Act of 1933, as amended or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein. There shall not be any offer, solicitation of an offer to buy, or sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. On September 28, 2016, the Company filed a prospectus supplement with the SEC relating to such shares of common stock, and copies of the prospectus supplement and the accompanying base prospectus relating to this offering may be obtained at the SEC's website at http://www.sec.gov , or from H.C. Wainwright & Co. by e-mailing placements@hcwco.com .

About Apricus Biosciences, Inc. Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus’ commercial product, Vitaros®, for the treatment of erectile dysfunction, is approved in Canada and certain countries in Europe, Latin America and the Middle East and is being commercialized in several countries in Europe. In September 2015, Apricus in-licensed the U.S. development and commercialization rights for Vitaros from Allergan. Apricus’ marketing partners for Vitaros include Recordati Ireland Ltd. (Recordati), Ferring International Center S.A. (Ferring Pharmaceuticals), Laboratoires Majorelle, Bracco S.p.A., Mylan NV and Elis Pharmaceuticals Ltd. Apricus currently has one active product candidate, RayVa™, its product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon.

For further information on Apricus, visit http://www.apricusbio.com .

*Vitaros® is a registered trademark of NexMed International Limited. Such trademark is registered in certain countries throughout the world and pending registration in the United States.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things: Apricus’ expectations on the anticipated use of proceeds from the offering. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside the control of Apricus, including, but not limited to: Apricus’ dependence on its commercial partners to carry out the commercial launch or grow sales of Vitaros in various territories and the potential for delays in the timing of commercial launches in additional countries; competition in the erectile dysfunction market and other markets in which Apricus and its partners operate; Apricus’ ability to obtain FDA and other requisite governmental approval for Vitaros; Apricus’ ability to comply with Nasdaq listing requirements; and other  risks and uncertainties inherent in Apricus’ business, including those described in the Company's periodic filings with the SEC and the prospectus supplement and related prospectus for this offering filed with the SEC. These forward-looking statements are made as of the date of this press release, and Apricus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in Apricus' most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC's website at www.sec.gov  or without charge from Apricus.

Investor Relations Contact: Matthew Beck mbeck@troutgroup.com The Trout Group (646) 378-2933

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Pepsi Faces Georgia Labor Pressure Ahead of Strike

Updated Category News Views 121

A Pre-Dawn Labor Test Is Brewing in Georgia At 2:30 in the morning, nobody gathers outside a distribution center for the scenery. More than 100 Pepsi-Cola drivers from Atlanta and Lithonia are slated to meet Tuesday, November 24, at the Pepsi Distribution Center in Lithonia, Georgia, with Teamsters General President Sean M. O'Brien joining them. That hour matters. It puts...

Continue Reading
Milwaukee County Contract Tests Wisconsin Labor Shift

Updated Category News Views 60

A unanimous first contract in a Milwaukee County department is not the sort of headline that rattles a trading screen, but it can tell you plenty about where the ground is moving. Public safety workers in the county Facilities Department have ratified their first agreement with Teamsters Local 344, according to the union. The vote matters less for any disclosed economic...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 149

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 83

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Straub's Court Win Raises Cost of Seven-Year Fight

Updated Category News Views 87

Seven years of courtroom smoke over an under-$80,000 lien is the sort of mess that makes any business owner grind his teeth. Palm Beach Polo says its president, Glenn Straub, has again prevailed against Jessica Nicodemo in Palm Beach County, following an earlier Broward County dismissal of related claims. The company also says Vice President Sal Spano received a directed...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Hoymiles Brings Plug-In Solar Flexibility to RE+ 2026

Updated Category News Views 105

A 1.8-kilogram box may not sound like much, but it captures where household solar is trying to go: smaller, less intimidating, and far easier to put to work. At RE+ 2026 in Las Vegas, Hoymiles laid out a residential lineup spanning plug-in solar, battery storage and conventional rooftop microinverters. This was not one flashy gadget looking for applause. It was a fairly...

Continue Reading

Top 5 Most Recently Viewed Articles

Hydreight Technologies Inc. Holds Successful Annual Meeting

Updated Category News Views 147

Successful Results from Hydreight Technologies Inc.'s Annual Meeting Hydreight Technologies Inc. (TSXV: NURS, OTC: HYDTF, FSE: SO6) proudly shares the positive outcomes from their recent Annual General Meeting. Conducted virtually, the meeting brought together shareholders who actively participated in decision-making. Shareholder Voting Outcomes During this significant...

Continue Reading
Discovering Leadership Themes in Anusia Gillespie's Novel

Updated Category News Views 146

Anusia Gillespie's Soul Toll: A Unique Literary Journey Soul Toll is gaining significant recognition for its imaginative storytelling which straddles the realms of ambition and awakening. This debut novel by Anusia Gillespie is becoming a staple not just in libraries, but also in yoga studios and leadership circles. Recognition from Kirkus Reviews The November issue of...

Continue Reading
First-Time Buyers' Guide to Stillwater's Housing Market

Updated Category News Views 64

The Challenge of Buying a Home in Stillwater Walking into Stillwater's housing market as a first-time buyer is like stepping onto a high-wire act. You're balancing dreams with dollars, all while the ground beneath you keeps shifting. What stands out from HelloNation's deep dive into this market, featuring Page Provence of Fisher Provence Realtors Inc., is that knowledge...

Continue Reading
Celebrating Excellence: National Catholic Reporter's 70 Awards

Updated Category News Views 127

Outstanding Achievement in Catholic Journalism The National Catholic Reporter (NCR) and its affiliated platforms, such as Global Sisters Report (GSR) and EarthBeat, have recently achieved remarkable recognition in the realm of Catholic media. With over 70 awards at the prestigious Catholic Media Awards, NCR has reaffirmed its dedication to delivering independent...

Continue Reading
Centessa Pharmaceuticals Prepares for Major Investor Events

Updated Category News Views 50

Centessa Pharmaceuticals' Upcoming Investor Conferences Centessa Pharmaceuticals plc (Nasdaq: CNTA), a pioneering clinical-stage pharmaceutical company, is set to mark its presence in several prominent investor conferences. The company's mission is to discover and develop transformative medicines aimed at enhancing patient outcomes. Guggenheim Healthcare Innovation...

Continue Reading